To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
Phase 3
Completed
- Conditions
- Seizure Disorder, Partial
- Registration Number
- NCT00141388
- Lead Sponsor
- Pfizer
- Brief Summary
To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 455
Inclusion Criteria
- Must have met the inclusion criteria for the preceding double-blind study
- Have received double-blind study medication and wish to receive open-label pregabalin.
Exclusion Criteria
- Cannot have absence seizures.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety Efficacy
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of pregabalin in modulating voltage-gated calcium channels for partial seizure control?
How does pregabalin compare to standard-of-care antiepileptic drugs in long-term seizure reduction and safety profiles?
What biomarkers correlate with improved seizure outcomes in pregabalin-treated patients with focal epilepsy?
What adverse events are associated with pregabalin long-term use in partial seizure populations and how are they managed?
How does pregabalin combination therapy with other antiepileptic drugs affect seizure control in drug-resistant epilepsy?
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇨🇦Montreal, Quebec, Canada
Pfizer Investigational Site🇨🇦Montreal, Quebec, Canada